withanolides has been researched along with Nervous-System-Diseases* in 2 studies
1 review(s) available for withanolides and Nervous-System-Diseases
Article | Year |
---|---|
The DJ1-Nrf2-STING axis mediates the neuroprotective effects of Withaferin A in Parkinson's disease.
The pathogenesis of Parkinson's disease (PD) remains unclear, and there is no disease-modifying agent for PD. Withaferin A (WA), a naturally occurring compound, has emerged as a neuroprotective agent. However, the mechanisms by which WA is neuroprotective in PD are unknown. Here we show that WA protected against loss of dopaminergic neurons, neuroinflammation, and motor deficits in MPTP-induced PD mouse models. Whole-genome deep sequencing analysis combined with Meta-analysis of human PD studies reveal that DJ1, Nrf2, and STING in substantia nigra pars compacta (SNc) are linked to anti-PD effect of WA. We found that WA activated DJ1 and Nrf2, and suppressed STING within SNc; and overexpression of STING in SNc dampened the effect of WA. Using genetically modified mice (DJ1-KO, Nrf2-KO, STING Topics: Aged; Animals; Disease Models, Animal; Humans; Male; Mice; Nervous System Diseases; Neuroprotective Agents; NF-E2-Related Factor 2; Parkinson Disease; Transfection; Withanolides | 2021 |
1 other study(ies) available for withanolides and Nervous-System-Diseases
Article | Year |
---|---|
Actin microfilament aggregation induced by withaferin A is mediated by annexin II.
The actin cytoskeleton supports diverse cellular processes such as endocytosis, oriented growth, adhesion and migration. The dynamic nature of the cytoskeleton, however, has made it difficult to define the roles of the many accessory molecules that modulate actin organization, especially the multifunctional adapter protein annexin II. We now report that the compound withaferin A (1) can alter cytoskeletal architecture in a previously unknown manner by covalently binding annexin II and stimulating its basal F-actin cross-linking activity. Drug-mediated disruption of F-actin organization is dependent on annexin II expression by cells and markedly limits their migratory and invasive capabilities at subcytotoxic concentrations. Given the extensive ethnobotanical history of withaferin-containing plant preparations in the treatment of cancer and inflammatory and neurological disorders, we suggest that annexin II represents a feasible, previously unexploited target for therapeutic intervention by small-molecule drugs. Topics: Actin Cytoskeleton; Actins; Animals; Annexin A2; Anti-Inflammatory Agents; Antineoplastic Agents; Binding Sites; Cattle; Cell Line; Cell Membrane; Cytoskeleton; Dose-Response Relationship, Drug; Ergosterol; Microfilament Proteins; Nervous System Diseases; Time Factors; Withanolides | 2006 |